Increased IFNγ and TNFα expression in both tumor and plasma; Partial responses in 2/45 patients (DLBCL and squamous-cell bladder carcinoma); 15/45 patients with stable disease. This evidence concerns the gene IFNG and diffuse large B-cell lymphoma.